ClinicalTrials.gg
CompletedNCT05772169Updated Jan 20, 2025

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

A Phase 4 interventional study of Mifepristone 300 MG [Korlym] and Placebo for mifepristone in Hypercortisolism and Diabetes Mellitus, Type 2, sponsored by Corcept Therapeutics. Completed at 36 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Corcept Therapeutics · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,113
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Cushing Syndrome by Corcept Therapeutics — none open to participants now, 1 under way, none of them phase 3. Cushing Syndrome · Corcept Therapeutics.

Enrollment
Largest of 11
1,113 · median 35
Started
2023
the only one that year
Phase 4
Only one
of the 16
Registered
15th of 16
by date

Among the 16 studies in Cushing Syndrome by Corcept Therapeutics, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is the only one in phase 4, and was the 15th registered.

Cushing Syndrome

123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.

Browse Cushing Syndrome studies →

Open to participants now

None of the 16 studies in Cushing Syndrome by Corcept Therapeutics is open now. The open studies under Cushing Syndrome, anywhere →

Who these studies take

Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Cushing Syndrome by Corcept Therapeutics as a file.
02

Study summary

This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to control T2D despite receiving standard of care therapies.

Read the detailed description

This is a Phase 4 study with 2 parts at approximately 30 sites in the United States (US).

Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control T2D (HbA1c ≥7.5%) despite receiving standard-of-care therapies.

Patients from Part 1 Prevalence Phase who meet eligibility requirements can then enroll in Part 2 and will be randomized 2:1 to receive mifepristone or placebo once daily with food. Randomization will be stratified by presence of adenoma (yes/no).

Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to control T2D despite receiving standard of care therapies.

03

Conditions studied

  • Hypercortisolism
  • Diabetes Mellitus, Type 2

Keywords

  • Hypercortisolism
  • Diabetes Mellitus, Type 2 Uncontrolled
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For Part 1:

Inclusion Criteria:

Has difficult to control T2D ( ≥7.5% and ≤11.5%) based on HbA1c performed at screening.

AND Taking 3 or more anti-hyperglycemic drugs. OR Taking insulin and other anti-hyperglycemic drugs. OR Taking 2 or more anti-hyperglycemic drugs AND a.) the presence of 1 or more micro-vascular or macro-vascular complication (retinopathy, diabetic nephropathy and chronic kidney disease, diabetic neuropathy, atherosclerotic heart disease with diabetes); AND/OR b.) concomitant hypertension requiring 2 or more anti-hypertension medications.

  • Women on oral pills (OCPs) may be screened but must be willing and able to stop OCPs for at least 3 weeks prior to the dexamethasone suppression test.

Exclusion Criteria:

  • Has type 1 diabetes mellitus.
  • New-onset diabetes less than 1 year.
  • Systemic medications exposure (excluding inhalers or topical) within 3 months of screening.
  • Is pregnant or lactating. For women of , have a positive pregnancy test before dexamethasone administration. A woman of childbearing potential includes all women \<50 years old, women whose surgical sterilization was performed \<6 months ago, and women who have had a menstrual period in the last 12 months.
  • On hemodialysis or has end-stage renal disease.
  • Has severe untreated sleep apnea as judged by the Investigator.
  • Has excessive alcohol consumption (>14 units/week for male, >7 units/week for female) as judged by the Investigator.
  • Has severe psychiatric illness by history (such as schizophrenia or dementia) as judged by the Investigator.
  • Has severe medical or surgical illness as judged by the Investigator.
  • Is a night shift worker, i.e., is awake from approximately 11 PM to 7 AM.
  • Has taken any drug within 4 weeks prior to screening, or within less than 5 times the drug's half-life, whichever is longer.
  • Has had the diagnosis of Cushing syndrome or has used or plans to use any of the following treatments for Cushing syndrome:

    • Mifepristone, metyrapone, osilodrostat, ketoconazole, fluconazole, aminoglutethimide, etomidate, octreotide, larazotide, pasireotide, long-acting octreotide or pasireotide.
  • Has a history of or severe reaction to dexamethasone

For Part 2:

Inclusion Criteria:

  • Has completed Part 1 of the study with post-DST cortisol level of >1.8 μg/dL and dexamethasone level ≥140 ng/dL
  • Will have no change in, or initiation of, diabetes medications within 4 weeks prior to first study drug dose

Exclusion Criteria:

  • Has any change in status of exclusion criteria from Part 1
  • Requires inhaled glucocorticoid use and may require systemic glucocorticoids if their condition deteriorates during study
  • Has severe, poorly controlled hypertension at screening (defined as mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg); must be able to correct to a BP of \<160/100 mmHg before first dose of study drug
  • Has hypokalemia; must be able to correct to potassium level of ≥4.0 mEq/L before first dose of study drug
  • Has poorly controlled hyperthyroidism/hypothyroidism before first dose of study drug (confirmed by TSH or free thyroxine)
  • Has plans for adrenalectomy or adrenal nodulectomy
  • Has renal insufficiency ( \<30 mL/min/1.73m2)
  • Has liver test results >3x ( or AST) or >1.5x ULN
  • Takes drugs metabolized by and CYP3A substrates with narrow therapeutic ranges
  • Receiving systemic corticosteroids that cannot be discontinued
  • Uses hormonal contraceptives
  • Has a history of unexplained vaginal bleeding, endometrial hyperplasia with atypia, or endometrial carcinoma
  • Is pregnant or lactating
  • Has a known hypersensitivity to mifepristone or any of the product components
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,113 participants (actual)

Study arms

  • Experimental
    Mifepristone 300 mg

    Randomized to receive 300 mg mifepristone, titrated to 600 mg mifepristone after 4 weeks with an opportunity to increase to 900 mg mifepristone at week 8 or 12

    Drug: Mifepristone 300 MG [Korlym]

  • Placebo comparator
    Placebo

    Patients who meet the entry criteria for the Study C-1073-310 will be randomized to receive placebo for 24 weeks

    Drug: Placebo for mifepristone

Interventions

  • Mifepristone tablets for once daily oral dosing

  • DrugPlacebo for mifepristone

    Placebo tablets for once daily oral dosing

06

What researchers measure

Primary outcomes

  1. Part 1 Prevalence Phase: Prevalence of Hypercortisolism

    Prevalence (percentage) of patients with hypercortisolism defined by dexamethasone suppression test (DST) \>1.8 μg/dL with dexamethasone level ≥140 ng/dL in patients with difficult to control T2D, defined as HbA1c ≥7.5%. despite receiving standard-of-care therapies.

    Time frame: Screening

  2. Part 2 Treatment Phase: Effect of Treatment on Hypercortisolism with Abnormal Adrenal CT Scan

    Change in HbA1c from baseline (at randomization) to 24 weeks in patients with hypercortisolism and abnormal adrenal CT scan who have difficult to control T2D despite receiving standard of care therapies, treated with mifepristone versus placebo.

    Time frame: Baseline Day 1 to week 24

  3. Part 2 Treatment Phase: Effect of Treatment on Hypercortisolism without Abnormal Adrenal CT Scan

    Change in HbA1c from baseline (at randomization) to 24 weeks in patients with hypercortisolism and normal adrenal CT scan who have difficult to control T2D despite receiving standard of care therapies, treated with mifepristone versus placebo.

    Time frame: Baseline Day 1 to week 24

Secondary outcomes

  1. Part 1 Prevalence Phase: Origin of Hypercortisolism

    Percentage of patients with/without abnormal adrenal CT scan.

    Time frame: Screening

  2. Part 1 Prevalence Phase: Patient Characteristics

    Clinical and/or laboratory characteristics of patients with hypercortisolism and of patients with hypercortisolism with/without abnormal adrenal CT scan.

    Time frame: Screening

  3. Part 2 Treatment Phase: Effect of Treatment

    Change in anti-diabetes medication from baseline (at randomization) to 24 weeks in patients with hypercortisolism with/without abnormal adrenal CT scan who have difficult to control T2D despite receiving standard-of-care therapies, treated with mifepristone versus placebo.

    Time frame: Baseline Day 1 to week 24

  4. Part 2 Treatment Phase: Effect of Treatment

    Change from baseline (at randomization) to 24 weeks in body weight, body mass index, waist circumference, other glycemic metrics, blood pressure, quality of life, antihypertensive medications, etc. in patients with hypercortisolism with/without abnormal adrenal CT scan treated with mifepristone versus placebo.

    Time frame: Baseline Day 1 to week 24

07

Study locations

36 sites
  • Site 407
    Escondido, California 92025, United States
  • Site 379
    Gardena, California 90247, United States
  • Site 378
    Huntington Park, California 90255, United States
  • Site 406
    La Jolla, California 92037, United States
  • Site 373
    Los Angeles, California 90057, United States
  • Site 387
    Tarzana, California 91356, United States
  • Site 375
    Torrance, California 90502, United States
  • Site 444
    Edgewater, Florida 32132, United States
  • Site 015
    Fort Lauderdale, Florida 33312, United States
  • Site 009
    Atlanta, Georgia 30303, United States
  • Site 097
    Atlanta, Georgia 30318, United States
  • Site 046
    Covington, Kentucky 41011, United States
  • Site 061
    Metairie, Louisiana 70006, United States
  • Site 377
    New Orleans, Louisiana 70112, United States
  • Site 205
    New Orleans, Louisiana 70121, United States
  • Site 410
    Baltimore, Maryland 21239, United States
  • Site 394
    Hyattsville, Maryland 20782, United States
  • Site 067
    Boston, Massachusetts 02115, United States
  • Site 074
    Ann Arbor, Michigan 48109, United States
  • Site 371
    Las Vegas, Nevada 89128, United States
  • Site 070
    Albany, New York 12208, United States
  • Site 411
    Smithtown, New York 11787, United States
  • Site 181
    Chapel Hill, North Carolina 27514, United States
  • Site 059
    Wilmington, North Carolina 28401, United States
  • Site 436
    Cincinnati, Ohio 45219, United States
  • Site 042
    Cleveland, Ohio 44195, United States
  • Site 077
    Columbus, Ohio 43210, United States
  • Site 195
    Columbus, Ohio 43215, United States
  • Site 435
    Grants Pass, Oregon 97527, United States
  • Site 049
    Portland, Oregon 97239, United States
  • Site 456
    Cedar Park, Texas 78613, United States
  • Site 370
    Dallas, Texas 75230, United States
  • Site 408
    Lufkin, Texas 75904, United States
  • Site 054
    San Antonio, Texas 78207, United States
  • Site 369
    San Antonio, Texas 78229, United States
  • Site 405
    Seattle, Washington 98108, United States
08

References and documents

Individual participant data

Plan to share: Yes — Upon study completion, results will be presented at relevant scientific congresses and published in a peer-reviewed journal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Nov 2024, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Mar 16, 2023
StartActual
Mar 31, 2023
Primary completionActual
Nov 19, 2024
CompletionActual
Dec 18, 2024
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05772169
Responsible party
Sponsor
First posted
Mar 16, 2023
Start date
Mar 31, 2023
Primary completion
Nov 19, 2024
Completion
Dec 18, 2024
Last update
Jan 20, 2025

Study contacts

Daniel Einhorn, MD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mifepristone

Start the discussion